메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Erlotinib-gemcitabine combined chemotherapy is considered as the standard treatment for unresectable pancreaticcancer. This study aimed to determine the clinical factors associated with response to this treatment. Materials and Methods: This retrospective study included 180 patients with unresectable pancreatic cancer who received ≥2 cyclesof gemcitabine-erlotinib combination therapy as first-line palliative chemotherapy between 2006 and 2014. “Long-term response”was defined as tumor stabilization after >6 chemotherapy cycles. Results: The median progression-free survival (PFS) and overall survival (OS) were 3.9 and 8.1 months, respectively. On univariateanalysis, liver metastasis (p=0.023) was negatively correlated with long-term response. Locally advanced stage (p=0.017), a history ofstatin treatment (p=0.01), and carcinoembryonic antigen levels <4.5 (p=0.029) had a favorable effect on long-term response. Onmultivariate analysis, a history of statin treatment was the only independent favorable factor for long-term response (p=0.017). Prognosticfactors for OS and PFS were significantly correlated with liver metastasis (p=0.031 and 0.013, respectively). A history of statintreatment was also significantly associated with OS after adjusting for all potential confounders (hazard ratio, 0.48; 95% confidenceinterval, 0.26–0.92; p=0.026). Conclusion: These results suggest that statins have a favorable effect on “long-term response” to gemcitabine-erlotinib chemotherapyin unresectable pancreatic cancer patients. Statins may have a chemoadjuvant role in stabilizing long-term tumor growth.

목차

등록된 정보가 없습니다.

참고문헌 (36)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0